Budrejko Szymon, Kempa Maciej, Przybylski Andrzej
Department of Cardiology and Electrotherapy, Medical University of Gdansk, 80-210 Gdansk, Poland.
1st Department of Cardiology with the Acute Coronary Syndromes Subdivision, Clinical Provincial Hospital No. 2, 35-310 Rzeszow, Poland.
Rev Cardiovasc Med. 2023 Jul 10;24(7):195. doi: 10.31083/j.rcm2407195. eCollection 2023 Jul.
An implantable cardioverter-defibrillator (ICD) was developed to provide protection against sudden cardiac death. Despite being effective in terminating ventricular arrhythmias, traditional transvenous ICDs appeared over time to have certain limitations related to the need for vascular access and the presence of foreign material inside the circulatory system (namely lead failure and infections). A subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to overcome those limitations and to provide prevention against sudden cardiac death from outside the cardiovascular system. Utilization of that modern method of treatment is constantly increasing worldwide, and new centers incorporate implantation of that system in their portfolio. This review aims to present the most relevant issues related to S-ICD implantation procedure, based on experience of the authors and an extensive literature search.
植入式心脏复律除颤器（ICD）的研发旨在预防心源性猝死。尽管传统经静脉ICD在终止室性心律失常方面有效，但随着时间推移，其似乎存在一些与血管通路需求以及循环系统内存在异物（即导线故障和感染）相关的局限性。皮下植入式心脏复律除颤器（S-ICD）得以研发，以克服这些局限性，并从心血管系统外部预防心源性猝死。这种现代治疗方法在全球的应用正在不断增加，新的中心也将该系统的植入纳入其业务范围。基于作者的经验和广泛的文献检索，本综述旨在介绍与S-ICD植入手术相关的最相关问题。
